2025
Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis
Sakuma I, Gaspar R, Nasiri A, Dufour S, Kahn M, Zheng J, LaMoia T, Guerra M, Taki Y, Kawashima Y, Yimlamai D, Perelis M, Vatner D, Petersen K, Huttasch M, Knebel B, Kahl S, Roden M, Samuel V, Tanaka T, Shulman G. Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2502978122. PMID: 40310463, PMCID: PMC12067271, DOI: 10.1073/pnas.2502978122.Peer-Reviewed Original ResearchConceptsCholine-deficient l-amino acid-defined high-fat dietBempedoic acidLiver fibrosisLiver diseaseL-amino acid-defined high-fat dietAdvanced liver diseaseCholesterol contentHSD17B13 variantsHigh-fat dietTotal liver cholesterol contentTreated miceActivate signaling pathwaysVariant rs738409Liver cholesterol contentLiver lipidsFibrotic responsePromote inflammationTherapeutic approachesSteatotic liver diseaseDietary cholesterol supplementationFibrosisHuman liver samplesI148MAntisense oligonucleotidesProgressive form
2024
European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care
Carbone M, Neuberger J, Rowe I, Polak W, Forsberg A, Fondevila C, Mantovani L, Nardi A, Colli A, Rockell K, Schick L, Cristoferi L, Oniscu G, Strazzabosco M, Cillo U. European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care. Transplant International 2024, 36: 12190. PMID: 38332850, PMCID: PMC10850237, DOI: 10.3389/ti.2023.12190.Peer-Reviewed Original ResearchConceptsValue-based health careOutcome measuresEuropean Society of Organ TransplantationLiver transplantationDevelopment of outcome measuresConsensus statementOrgan transplantationValue-basedPatient-focusedAdvanced liver diseaseHealth careMultidisciplinary teamLiver diseaseTransplantationLife-savingEuropean Society for Organ TransplantationPatients
2023
Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations
Sellers Z, Assis D, Paranjape S, Sathe M, Bodewes F, Bowen M, Cipolli M, Debray D, Green N, Hughan K, Hunt W, Leey J, Ling S, Morelli G, Peckham D, Pettit R, Philbrick A, Stoll J, Vavrina K, Allen S, Goodwin T, Hempstead S, Narkewicz M. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology 2023, 79: 1220-1238. PMID: 37934656, PMCID: PMC11020118, DOI: 10.1097/hep.0000000000000646.Peer-Reviewed Original ResearchConceptsAdvanced liver diseaseCystic fibrosisLiver diseaseHepatobiliary involvementHepatobiliary complicationsCF-associated liver diseasePubMed literature searchCystic fibrosis screeningScreening ultrasoundPortal hypertensionOutcome questionsLiver biopsyLiver failureMultilobular cirrhosisFibrosis screeningConsensus recommendationsFull-text reviewHepatobiliary diseaseCF FoundationLiterature searchThirty-oneCF outcomesMultidisciplinary committeeDiseaseComplicationsOutcomes of patients with advanced liver disease undergoing cardiac surgery
Pétursson I, Amabile A, Degife E, Morrison A, Waldron C, Bin Mahmood S, Ragnarsson S, Krane M, Geirsson A. Outcomes of patients with advanced liver disease undergoing cardiac surgery. JTCVS Open 2023, 16: 532-539. PMID: 38204635, PMCID: PMC10774984, DOI: 10.1016/j.xjon.2023.07.001.Peer-Reviewed Original ResearchAdvanced liver diseaseCTP class ALiver diseaseCardiac surgeryLogistic regression analysisInferior outcomesEnd-stage liver disease (MELD) scoreMultivariate logistic regression analysisCTP class BPugh class ALiver Disease scoreOutcomes of patientsPeripheral vascular diseaseRegression analysisClass AClass BChild-TurcotteHospital mortalityPerioperative outcomesPostoperative complicationsRenal failureIndependent predictorsFemale sexVascular diseaseRisk factorsHepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project
Rogal S, Taddei T, Monto A, Yakovchenko V, Patton H, Merante M, Spoutz P, Chia L, Yudkevich J, Aytaman A, Rabiee A, John B, Blechacz B, Cai C, Gilles H, Shah A, McCurdy H, Puri P, Jou J, Mazhar K, Dominitz J, Anwar J, Morgan T, Ioannou G. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project. Clinical Gastroenterology And Hepatology 2023, 22: 324-338. PMID: 37460005, PMCID: PMC10788380, DOI: 10.1016/j.cgh.2023.07.002.Peer-Reviewed Original ResearchGood performance statusCurative treatmentHCC screeningHCC diagnosisPerformance statusEarly-stage diagnosisMedical record extractionAdvanced liver diseaseReceipt of treatmentStage diagnosisPreventative health care servicesHepatocellular carcinoma stageVA primary careQuality improvement projectHealth care servicesHepatocellular carcinoma diagnosisElectronic health recordsCirrhosis careNoncurative treatmentLiver diseaseCancer screeningPrimary careMultivariable modelCarcinoma stageNew diagnosis
2022
Metabolic Syndrome and Liver Cancer
Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. 2022, 87-104. DOI: 10.1007/978-3-030-41683-6_51.Peer-Reviewed Original ResearchHepatitis B virusNonalcoholic fatty liver diseaseMetabolic syndromeRisk factorsHepatocellular carcinomaLiver diseaseLiver cancerParticular hepatitis B virusIncidence of HCCAdvanced liver diseaseIndependent risk factorFatty liver diseaseType 2 diabetesUnderlying pathogenic mechanismsHepatic manifestationHCC incidenceViral hepatitisAdvanced fibrosisSignificant morbidityDiabetes leadsTime patientsB virusHCC riskHigh prevalenceLower incidenceCOVID-19 and the liver: a narrative review of the present state of knowledge
Thandassery RB, Dranoff JA, Perisetti A, Taddei T. COVID-19 and the liver: a narrative review of the present state of knowledge. Translational Gastroenterology And Hepatology 2022, 0: 0-0. PMID: 36300154, PMCID: PMC9468988, DOI: 10.21037/tgh-20-243.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseLiver diseaseLiver injuryComorbid conditionsAcute respiratory distress syndromeDirect viral cytotoxicityNon-immunosuppressed patientsAdvanced liver diseaseLiver function testsThird of patientsEpithelial cellsRespiratory distress syndromeResolution of diseaseResolution of illnessOngoing pandemicNovel corona virus diseaseType 2 pneumocytesCOVID-19Biliary epithelial cellsGastrointestinal epithelial cellsCorona Virus DiseaseLiver dysfunctionDistress syndromeFunction testsUninterrupted care
2021
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease
Fix OK, Blumberg EA, Chang K, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ, Group F. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology 2021, 74: 1049-1064. PMID: 33577086, PMCID: PMC8014184, DOI: 10.1002/hep.31751.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineCOVID-19 vaccineChronic liver diseaseLiver diseaseModerna mRNA COVID-19 vaccinesCoronavirus disease 2019 (COVID-19) infectionExpert panel consensus statementPrevious drug reactionsAdvanced liver diseaseLiver transplant recipientsAvailable COVID-19 vaccinesDisease 2019 infectionSevere hypersensitivity reactionsLocal site reactionsCare of patientsClinical trial participantsHealth care providersLT recipientsTransplant recipientsAdult patientsImmunosuppressed patientsSystemic reactionsHypersensitivity reactionsSite reactionsVaccine efficacyFactors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease
Kanwal F, Hernaez R, Liu Y, Taylor TJ, Rana A, Kramer JR, Naik AD, Smith D, Taddei T, Asch SM. Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Internal Medicine 2021, 181: 949-959. PMID: 34028505, PMCID: PMC8145153, DOI: 10.1001/jamainternmed.2021.2051.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseAdvanced liver diseaseLiver diseaseLiver transplantationCohort studyMedical recordsOrgan transplantsVeterans Affairs Health Care SystemLower ratesRetrospective cohort studyWait-listed patientsAfrican American patientsComprehensive electronic medical recordsElectronic medical recordsHealth care systemReferral stepsLiver allograftsLiver transplantAdult patientsAlcohol etiologyLow annual incomePatient ageCurative therapyLiver cirrhosisSodium scoreXIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent in vitro and in vivo Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC
He L, Sehrawat T, Verma V, Navarro-Corcuera A, Sidhu G, Mauer A, Luo X, Katsumi T, Chen J, Shah S, Arab J, Cao S, Kashkar H, Gores G, Malhi H, Shah V. XIAP Knockdown in Alcohol-Associated Liver Disease Models Exhibits Divergent in vitro and in vivo Phenotypes Owing to a Potential Zonal Inhibitory Role of SMAC. Frontiers In Physiology 2021, 12: 664222. PMID: 34025452, PMCID: PMC8138467, DOI: 10.3389/fphys.2021.664222.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseLiver diseaseTreatment of ALDAggravated liver injuryAdvanced liver diseasePrimary hepatocytesBone marrow-derived macrophagesCaspase-3Marrow-derived macrophagesMechanisms of pathogenesisHuman liver tissueInflammatory markersInflammation markersLiver injuryCCl4 modelLiver steatosisClinical trialsCommon causeAnti-apoptotic proteinsKnockout micePeriportal regionHepatocyte apoptosisLiver tissueLow expressionALD modelMetabolic Syndrome and Liver Cancer
Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. 2021, 1-19. DOI: 10.1007/978-3-030-37482-2_51-1.Peer-Reviewed Original ResearchHepatitis B virusNonalcoholic fatty liver diseaseMetabolic syndromeRisk factorsHepatocellular carcinomaLiver diseaseLiver cancerParticular hepatitis B virusIncidence of HCCAdvanced liver diseaseIndependent risk factorFatty liver diseaseType 2 diabetesUnderlying pathogenic mechanismsHepatic manifestationHCC incidenceViral hepatitisAdvanced fibrosisSignificant morbidityDiabetes leadsTime patientsB virusHCC riskHigh prevalenceLower incidenceMortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation
Serper M, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE. Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation. Hepatology 2021, 73: 219-232. PMID: 32267547, PMCID: PMC7541418, DOI: 10.1002/hep.31264.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsEffect of anticoagulationAtrial fibrillationCause mortalityMarginal structural modelsHepatic decompensationIschemic strokeMajor adverse cardiovascular eventsAdvanced liver diseaseAdverse cardiovascular eventsIncident atrial fibrillationSplanchnic vein thrombosisPropensity-score matchingCardiovascular eventsOral anticoagulantsVein thrombosisFinal cohortLiver diseaseTime-dependent confoundingAnticoagulationLower incidenceMedical CenterCirrhosisWarfarinU.S. veterans
2020
Palliative Care in Cirrhosis: Beyond Misconceptions
Jakab S, Verma M, Navarro V, Taddei T. Palliative Care in Cirrhosis: Beyond Misconceptions. Current Treatment Options In Gastroenterology 2020, 18: 245-254. DOI: 10.1007/s11938-020-00283-1.Peer-Reviewed Original ResearchAdvanced liver diseasePalliative careLiver diseaseManagement of patientsDifferent patient populationsQuality of lifeLiver transplantationSupportive carePatient populationLiver cancerPractical updateMedical providersRoutine practicePatientsCareCirrhosisDelivery modeBest delivery modeDiseaseCaregiversTransplantationHepatologyClarification of goalsSymptomsCancerLiver Fibrosis Indices and Outcomes After Primary Intracerebral Hemorrhage
Parikh NS, Kamel H, Navi BB, Iadecola C, Merkler AE, Jesudian A, Dawson J, Falcone GJ, Sheth KN, Roh DJ, Elkind MSV, Hanley DF, Ziai WC, Murthy SB, Hanley D, Butcher K, Davis S, Gregson B, Lees K, Lyden P, Mayer S, Muir K, Steiner T. Liver Fibrosis Indices and Outcomes After Primary Intracerebral Hemorrhage. Stroke 2020, 51: 830-837. PMID: 31906832, PMCID: PMC7048169, DOI: 10.1161/strokeaha.119.028161.Peer-Reviewed Original ResearchConceptsPrimary intracerebral hemorrhageNonalcoholic fatty liver disease fibrosis scoreAspartate aminotransferase-platelet ratio indexAminotransferase-platelet ratio indexLiver fibrosis indexIntracerebral hemorrhageAdmission hematoma volumeHematoma volumeHematoma expansionFibrosis-4Fibrosis indexFibrosis scoreLiver diseaseMajor disabilityRatio indexNormal liver chemistriesAdvanced liver diseaseFibrosis-4 scoreRetrospective cohort studyPlatelet ratio indexPoor stroke outcomesSubclinical liver diseaseLogistic regression modelsLiver chemistriesRadiological outcomes
2019
The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance
Sellers CM, Uhlig J, Ludwig JM, Taddei T, Stein SM, Lim JK, Kim HS. The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. Cancer Medicine 2019, 8: 5948-5958. PMID: 31436905, PMCID: PMC6792508, DOI: 10.1002/cam4.2251.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaPrivate insuranceInsurance statusMedicaid patientsCox proportional hazards modelAdvanced liver diseaseChild-Pugh BHigh MELD scoreAmerican Joint CommitteeKaplan-Meier curvesProportional hazards modelInsurance groupsMELD scoreOverall survivalIndependent predictorsLiver diseaseMultivariable analysisTumor burdenCancer RegistryTumor sizePotential confoundersSurvival differencesCancer stageUnivariate analysisC diseaseReversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
Beshlawy AE, Murugesan V, Mistry PK, Eid K. Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy. Molecular Genetics And Metabolism Reports 2019, 20: 100490. PMID: 31309038, PMCID: PMC6606832, DOI: 10.1016/j.ymgmr.2019.100490.Peer-Reviewed Original ResearchImiglucerase enzyme replacement therapyEnzyme replacement therapyHepatopulmonary syndromeReplacement therapyGaucher diseaseLiver diseaseRecombinant enzyme replacement therapyAdvanced liver diseaseLife-threatening complicationsAdvanced fibrosisFibrotic featuresMassive hepatomegalySplenectomized patientsClinical manifestationsEnzyme therapySyndromeTherapyDisease pathologyDiseaseComplicationsMacrophagesCirrhosisHepatomegalyPatientsFibrosisUpdates on Chronic HBV: Current Challenges and Future Goals
Lee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Current Treatment Options In Gastroenterology 2019, 17: 271-291. PMID: 31077059, DOI: 10.1007/s11938-019-00236-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTenofovir alafenamide fumarateGlobal public health problemPublic health problemChronic HBVHepatocellular carcinomaLiver failureCurative treatmentLiver diseaseAntiviral therapyClinical trialsHealth problemsLaboratory safety parametersNew treatment recommendationsAdvanced liver diseaseComplications of cirrhosisCurrent antiviral therapiesEarly phase studiesLong-term useNucleotide analog drugsHBV reactivationLiver decompensationFunctional cureTherapeutic armamentariumTreatment recommendationsImproved outcomes
2018
Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B
Nguyen MH, Ozbay AB, Liou I, Meyer N, Gordon SC, Dusheiko G, Lim JK. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. Journal Of Hepatology 2018, 70: 24-32. PMID: 30287341, DOI: 10.1016/j.jhep.2018.09.021.Peer-Reviewed Original ResearchConceptsAdvanced liver diseaseCompensated liver diseaseLiver diseaseDisease severityCause inpatientLiver transplantHepatitis BHealthcare utilizationHepatocellular carcinomaHigh emergency department (ED) utilizationHighest mean annual costCause inpatient admissionsChronic hepatitis BDisease statesHealthcare resource utilizationLiver disease groupEmergency department utilizationEmergency room visitsHepatocellular carcinoma groupProgressive disease statesPharmaceutical utilizationMean annual costLiver disease statesProgressive diseaseHepatitis B.
2017
Periprocedural Bleeding Risk Assessment in Chronic Liver Disease
Fortune B, Madoff D, May B. Periprocedural Bleeding Risk Assessment in Chronic Liver Disease. Digestive Disease Interventions 2017, 01: 306-312. DOI: 10.1055/s-0038-1629916.Peer-Reviewed Original ResearchAdvanced liver diseaseChronic liver diseaseLiver diseaseCLD patientsInternational normalized ratio testsBleeding Risk AssessmentLaboratory abnormalitiesUnnecessary transfusionsBlood productsInvasive proceduresProcedure delaysPatientsDiseaseCoagulopathyPotential harmRiskLaboratory testsBleedingTransfusionRisk assessmentAbnormalitiesClinicians
2016
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C, Association E. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal Of Hepatology 2016, 65: 524-531. PMID: 27212241, DOI: 10.1016/j.jhep.2016.05.010.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOral direct acting antiviralsClinical improvementChild-PughLiver transplantationActing antiviralsAdvanced liver diseaseChronic hepatitis CLiver transplant candidatesLow MELD scoresRemarkable clinical improvementHepatitis C virusDAA therapyDelta MELDDelta-albuminDAA combinationsHepatitis CMELD scoreViral eradicationCumulative incidenceLiver dysfunctionTransplant candidatesAntiviral therapyLiver diseaseLiver function
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply